MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Risk Thresholds of Levodopa Dose for Dyskinesia in Chinese Patients with Parkinson’s Disease: A Pilot Study

GL. Liu, T. Feng (Beijing, China)

Meeting: 2019 International Congress

Abstract Number: 140

Keywords: Dyskinesias, Levodopa(L-dopa)

Session Information

Date: Monday, September 23, 2019

Session Title: Clinical Trials, Pharmacology and Treatment

Session Time: 1:45pm-3:15pm

Location: Agora 3 West, Level 3

Objective: The objective of this study was to investigate the thresholds of levodopa dose to reduce the risk for dyskinesia in a Chinese PD population.

Background: Levodopa is widely used to treat Parkinson’s Disease (PD), and its long-term therapy may induce dyskinesia in a dose-dependent manner. However, the threshold dose with a relatively low risk for dyskinesia has not been determined.

Method: Demographic, clinical profiles and detailed information of dopaminergic drugs were recorded for 403 Chinese PD patients in treatment with various doses of levodopa. Variables were compared between dyskinesia and non-dyskinesia groups. Multivariate logistic regression analysis was used to assess the association between levodopa dose-related variables and dyskinesia. Receiver Operating Characteristic curve and Decision Tree Classification model were used to investigate the optimal levodopa dose to best separate the dyskinesia group from the non-dyskinesia group.

Results: Four hundred and three patients were investigated in our study, among whom 110 patients developed dyskinesia. The demographic and clinical characteristics of the non-dyskinesia and dyskinesia groups were listed in Table1. Patients with dyskinesia tended to have a lower weight and age at onset of PD, higher percentage of female and wearing-off, longer duration of disease and levodopa treatment, higher H-Y stage and UPDRS Part III scores, higher levodopa dose (daily levodopa dose, cumulative levodopa dose, daily levodopa dose adjusted to weight) and levodopa equivalent dose(LEED) of total dopaminergic drug than those without dyskinesia. After adjusted for demographical and clinical variables, levodopa dose factors were still associated with dyskinesia(Table2). To ensure that the proposed doses were clinically practical, an appropriate threshold dose for levodopa was determined based on the expert opinion of the authors and the overall performance of prediction(Table3). Finally, daily levodopa dose at 400mg/day and 6.3mg/kg/day, cumulative levodopa dose at 536g, daily LEED at 595 mg/day and 9.3 mg/kg/day, cumulative LEED at 592 g were proposed as the threshold doses for dyskinesia(Figure1).

Conclusion: In our pilot study, we evaluated the threshold doses of levodopa treatment to reduce the risk for dyskinesia. These data should be considered for the clinical prevention and management of dyskinesia in patients with PD.

Table1

Table2

Table3

Figure1

To cite this abstract in AMA style:

GL. Liu, T. Feng. Risk Thresholds of Levodopa Dose for Dyskinesia in Chinese Patients with Parkinson’s Disease: A Pilot Study [abstract]. Mov Disord. 2019; 34 (suppl 2). https://www.mdsabstracts.org/abstract/risk-thresholds-of-levodopa-dose-for-dyskinesia-in-chinese-patients-with-parkinsons-disease-a-pilot-study/. Accessed June 15, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/risk-thresholds-of-levodopa-dose-for-dyskinesia-in-chinese-patients-with-parkinsons-disease-a-pilot-study/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley